Deciphering the role of lysosomal membrane permeabilization in Diabetic Cardiac Injury

This study, conducted at the New York Institute of Technology College of Osteopathic Medicine investigates the cellular mechanisms by which hyperglycemia contributes to diabetic cardiac injury, focusing on lysosomal membrane permeabilization (LMP) and the role of Cathepsin D (CTSD). Hyperglycemia is established as an independent risk factor for diabetic heart failure, yet the precise intracellular pathways driving cardiomyocyte death under high glucose remain incompletely understood. Previous observations have linked lysosomal dysfunction to diabetic cardiac pathology, and the present work tests the hypothesis that high glucose conditions induce LMP, leading to release of lysosomal proteases such as CTSD and subsequent cardiomyocyte injury.

Using cultured neonatal rat ventricular cardiomyocytes (NRVC) exposed to varied glucose concentrations (5.5, 17, or 30 mmol/l for 72 hours) and appropriate osmotic controls, the study evaluated lysosomal pH, membrane integrity, CTSD expression and localization, and cell death outcomes. High glucose reduced the number of lysosomes exhibiting an acidic pH, as measured with a fluorescent pH indicator, indicating impaired lysosomal acidification or function. High glucose also induced lysosomal membrane injury, demonstrated by accumulation of Galectin3-RFP puncta, a marker of damaged lysosomal membranes. This lysosomal damage was accompanied by leakage of CTSD, an aspartic protease normally confined to the lysosomal lumen.

Importantly, CTSD protein expression was increased in cardiomyocytes cultured under high glucose and in the hearts of two mouse models of type 1 diabetes, indicating that CTSD upregulation is associated with diabetic conditions in vitro and in vivo. Functional experiments established a causal role for CTSD in high glucose–induced cardiomyocyte death: knockdown of CTSD with siRNA or pharmacologic inhibition of CTSD activity with pepstatin A markedly diminished high glucose–induced cardiomyocyte death. Conversely, overexpression of CTSD exacerbated cell death under high glucose. These manipulations support a model in which CTSD is not merely a marker of lysosomal disturbance but an active mediator of hyperglycemia-induced cardiomyocyte injury.

The study situates CTSD as a particularly relevant lysosomal protease in this context because, unlike many lysosomal enzymes that lose activity in neutral cytosolic pH, CTSD retains functionality outside the acidic lysosomal lumen and has multiple physiological substrates in the cytosol. Thus, when LMP permits CTSD escape into the cytosol, CTSD can remain active and contribute directly to cellular injury pathways.

Collectively, the findings reported by Kobayashi and colleagues indicate that high glucose conditions promote lysosomal dysfunction and membrane permeabilization, increase CTSD expression, and facilitate CTSD release into the cytosol, where CTSD activity contributes to cardiomyocyte death. By linking hyperglycemia, LMP, and CTSD-mediated injury, this work provides mechanistic insight into how elevated glucose can drive diabetic cardiomyopathy and suggests CTSD and lysosomal membrane stability as potential targets for further investigation in diabetic cardiac injury.